[go: up one dir, main page]

AR096123A1 - Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coagulación - Google Patents

Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coagulación

Info

Publication number
AR096123A1
AR096123A1 ARP140101748A ARP140101748A AR096123A1 AR 096123 A1 AR096123 A1 AR 096123A1 AR P140101748 A ARP140101748 A AR P140101748A AR P140101748 A ARP140101748 A AR P140101748A AR 096123 A1 AR096123 A1 AR 096123A1
Authority
AR
Argentina
Prior art keywords
procedures
compositions
coagulation
factory
proteins
Prior art date
Application number
ARP140101748A
Other languages
English (en)
Inventor
Aswad Fred
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of AR096123A1 publication Critical patent/AR096123A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se proporcionan conjugados para inducir tolerancia de la proteína factor de coagulación, en el que el conjugado comprende una proteína factor de coagulación o un fragmento antigénico o variante del mismo y un ligando Siglec. También se proporcionan composiciones farmacéuticas, procedimientos y kits que comprenden los conjugados.
ARP140101748A 2013-04-28 2014-04-28 Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coagulación AR096123A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361816790P 2013-04-28 2013-04-28

Publications (1)

Publication Number Publication Date
AR096123A1 true AR096123A1 (es) 2015-12-09

Family

ID=50846907

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101748A AR096123A1 (es) 2013-04-28 2014-04-28 Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coagulación

Country Status (11)

Country Link
US (1) US20160279252A1 (es)
EP (1) EP2991684B1 (es)
JP (1) JP2016519120A (es)
CN (1) CN105451774A (es)
AR (1) AR096123A1 (es)
CA (1) CA2910277A1 (es)
ES (1) ES2691041T3 (es)
HK (1) HK1217167A1 (es)
TW (1) TW201519900A (es)
UY (1) UY35545A (es)
WO (1) WO2014179184A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160060324A1 (en) * 2013-04-22 2016-03-03 James C. Paulson Methods and Compositions for Treating Bleeding Disorders
JP7626514B2 (ja) * 2016-05-20 2025-02-07 オクタファルマ アクチェン ゲゼルシャフト 改善された薬物動態を有する、グリコシル化ｖｗｆ融合タンパク質
CN108926719B (zh) * 2017-05-25 2020-09-01 北京格瑞特森生物医药科技有限公司 用c(RGD-ACP-K)修饰的长循环脂质体
WO2018225873A1 (ja) * 2017-06-09 2018-12-13 協和発酵キリン株式会社 核酸含有ナノ粒子
EP3839059A1 (en) * 2019-12-16 2021-06-23 CGT Enterprises, LLC Devices and methods for determining coagulation factor activities
EP4554622A2 (en) * 2022-07-13 2025-05-21 Osprey Biopharmaceuticals, Inc. Autoantigens engineered to suppress autoimmune response
CN116036244B (zh) * 2023-02-24 2023-09-19 北京基科晟斯医药科技有限公司 培重组人凝血因子VIII-Fc融合蛋白用于治疗含抑制物的血友病A的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
KR101237884B1 (ko) * 2003-12-03 2013-02-27 바이오제너릭스 에이지 글리코 peg화 과립구 콜로니 자극인자
JP4738346B2 (ja) * 2003-12-03 2011-08-03 ノヴォ ノルディスク アー／エス ＧｌｙｃｏＰＥＧ化された第ＩＸ因子
ES2821832T3 (es) * 2004-11-12 2021-04-27 Bayer Healthcare Llc Modificación de FVIII dirigida al sitio
US20100221763A1 (en) * 2005-10-17 2010-09-02 Health Research, Inc Specific Acceptors for Transferases to Saccharides and Method for Obtaining and Using Same
AU2010278721A1 (en) * 2009-07-31 2012-02-16 Bayer Healthcare Llc Modified factor IX polypeptides and uses thereof

Also Published As

Publication number Publication date
EP2991684A1 (en) 2016-03-09
UY35545A (es) 2014-11-28
WO2014179184A1 (en) 2014-11-06
ES2691041T3 (es) 2018-11-23
WO2014179184A8 (en) 2015-10-29
TW201519900A (zh) 2015-06-01
US20160279252A1 (en) 2016-09-29
CA2910277A1 (en) 2014-11-06
HK1217167A1 (zh) 2016-12-30
CN105451774A (zh) 2016-03-30
JP2016519120A (ja) 2016-06-30
EP2991684B1 (en) 2018-07-11

Similar Documents

Publication Publication Date Title
FR21C1030I2 (fr) Conjugué anticorps anti-her2-médicament
CL2023000198A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
IL270090B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CO2018005525A2 (es) Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab
EP3549589A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING MITOCHONDRIA
AR096123A1 (es) Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coagulación
EP3473270A4 (en) ANTIBODY-drug conjugate
MX2015015239A (es) Composiciones y metodos.
CO2018005433A2 (es) Conjugados de fármaco de anticuerpo her2 específicos de sitio
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
MX391989B (es) Conjugados de amatoxina y anticuerpos.
PE20150646A1 (es) Metodos de tratamiento de una tauopatia
PE20150892A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
MX385749B (es) Composiciones que comprenden una caseína y métodos para producir las mismas.
BR112016025291A2 (pt) conjugados de anticorpo anti-ptk7-fármaco
MX2017007585A (es) Anticuerpos anti-c10orf54 y usos de los mismos.
CU20150128A7 (es) Conjugados fármaco-anticuerpo
MX2016009862A (es) Conjugados de anticuerpo-farmaco hidrofilicos.
CR20150626A (es) Anticuerpos frente a ácidos teicoicos de pared y conjugados
SI3003386T1 (sl) Konjugati zdravila s protitelesci
BR112015024040A2 (pt) preparação alergênica
EP3355931C0 (en) PROTEIN CONJUGATES
IL263965A (en) Cleavable polymer drug conjugates
CO2017007316A2 (es) Formulación farmacéutica
LT3411076T (lt) Antikūno-vaisto konjugatai, kurių taikinys uparap

Legal Events

Date Code Title Description
FB Suspension of granting procedure